Search - tctmd.com

Displaying 421 - 440 of 626

Sort: Relevancy | Date

Presentation TCT 2016

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Presenter: Maurice Buchbinder, Horst Sievert, Caterina Gandolfo

October 31, 2016

Presentation TCT 2016

Real-time 3D Guidance in Recanalization of Interrupted Aorta

Presenter: Maurice Buchbinder, Horst Sievert, C. Huie Lin

October 31, 2016

Presentation TCT 2016

LAA Closure With Amplatzer Amulet: A Step-by-Step Approach

Presenter: Maurice Buchbinder, Horst Sievert, Apostolos Tzikas

October 31, 2016

Presentation TCT 2016

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Presenter: Maurice Buchbinder, Horst Sievert, C. Huie Lin

October 31, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Jamil Abdalla Saad

October 30, 2016

Presentation TCT 2016

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Josep Rodés-Cabau

October 30, 2016

Presentation TCT 2016

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Yat-Yin Lam

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Horst Sievert

October 30, 2016

Presentation TCT 2016

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Apostolos Tzikas

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Martin W. Bergmann

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Advertisement

Combined Single-Session Tavi With Edwards Sapien 3 Aortic Valve and Percutaneous Closure of the Left Atrial Appendage in a Elderly Comorbid Patient

Real-time 3D Guidance in Recanalization of Interrupted Aorta

LAA Closure With Amplatzer Amulet: A Step-by-Step Approach

Native RVOT Modification and Hybrid Transcatheter Pulmonary Valve Replacement

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content